Lisa M Wu1, Molly L Tanenbaum2, Marcel P J M Dijkers3, Ali Amidi4, Simon J Hall5, Frank J Penedo6, Michael A Diefenbach7. 1. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, 633 North St. Clair, Suite 19-073, Chicago, IL 60611, USA. Electronic address: lisa.wu1@northwestern.edu. 2. Department of Pediatrics, Stanford University School of Medicine, Palo Alto, CA, USA. Electronic address: mollyt@stanford.edu. 3. Department of Rehabilitation Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: Marcel.Dijkers@mountsinai.org. 4. Unit for Psychooncology and Health Psychology, Department of Oncology and Department of Psychology and Behavioural Sciences, Aarhus University Hospital & Aarhus University, Aarhus C., Denmark. Electronic address: ali@psy.au.dk. 5. Departments of Medicine and Urology, Northwell Health, Great Neck, NY, USA. Electronic address: Shall12@Northwell.edu. 6. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, 633 North St. Clair, Suite 19-073, Chicago, IL 60611, USA. Electronic address: fpenedo@northwestern.edu. 7. Departments of Medicine and Urology, Northwell Health, Great Neck, NY, USA. Electronic address: MDiefenbach@Northwell.edu.
Abstract
BACKGROUND: Few studies have investigated prostate cancer patients' experiences of cognitive functioning or neurobehavioral symptoms (i.e., behavioral changes associated with neurological dysfunction) following androgen deprivation therapy (ADT). METHODS: Semi-structured interviews conducted from the US by phone and in-person were used to explore and characterize the: 1) experience of cognitive and neurobehavioral functioning in non-metastatic prostate cancer patients undergoing ADT (n = 19) compared with patients who had not undergone ADT (n = 20); 2) perceived causes of cognitive and neurobehavioral symptoms; 3) impact of these symptoms on quality of life; and 4) strategies used to cope with or compensate for these symptoms. Neuropsychological performance was assessed to characterize the sample. RESULTS: Overall, ADT patients experienced marginally more cognitive problems than non-ADT (nADT) patients even though there were no significant differences between groups in neuropsychological performance. ADT patients also experienced more declines in prospective memory and multi-tasking than nADT patients. Significant proportions of participants in both groups also experienced retrospective memory, attention and concentration, and information processing difficulties. With respect to neurobehavioral symptoms, more ADT patients experienced emotional lability and impulsivity (both aspects of disinhibition) than nADT patients. Among the causes to which participants attributed declines, both groups attributed them primarily to aging. A majority of ADT patients also attributed declines to ADT. For both groups, increased cognitive and neurobehavioral symptoms negatively impacted quality of life, and most participants developed strategies to ameliorate these problems. CONCLUSION: ADT patients are more vulnerable to experiencing specific cognitive and neurobehavioral symptoms than nADT patients. This study highlights the importance of capturing: a) cognitive symptoms not easily detected using neuropsychological tests; b) neurobehavioral symptoms that can be confused with psychological symptoms, and c) causal beliefs that may affect how people cope with these symptoms. Effective interventions are needed to assist prostate cancer patients in managing these symptoms.
BACKGROUND: Few studies have investigated prostate cancerpatients' experiences of cognitive functioning or neurobehavioral symptoms (i.e., behavioral changes associated with neurological dysfunction) following androgen deprivation therapy (ADT). METHODS: Semi-structured interviews conducted from the US by phone and in-person were used to explore and characterize the: 1) experience of cognitive and neurobehavioral functioning in non-metastatic prostate cancerpatients undergoing ADT (n = 19) compared with patients who had not undergone ADT (n = 20); 2) perceived causes of cognitive and neurobehavioral symptoms; 3) impact of these symptoms on quality of life; and 4) strategies used to cope with or compensate for these symptoms. Neuropsychological performance was assessed to characterize the sample. RESULTS: Overall, ADTpatients experienced marginally more cognitive problems than non-ADT (nADT) patients even though there were no significant differences between groups in neuropsychological performance. ADTpatients also experienced more declines in prospective memory and multi-tasking than nADTpatients. Significant proportions of participants in both groups also experienced retrospective memory, attention and concentration, and information processing difficulties. With respect to neurobehavioral symptoms, more ADTpatients experienced emotional lability and impulsivity (both aspects of disinhibition) than nADTpatients. Among the causes to which participants attributed declines, both groups attributed them primarily to aging. A majority of ADTpatients also attributed declines to ADT. For both groups, increased cognitive and neurobehavioral symptoms negatively impacted quality of life, and most participants developed strategies to ameliorate these problems. CONCLUSION:ADTpatients are more vulnerable to experiencing specific cognitive and neurobehavioral symptoms than nADTpatients. This study highlights the importance of capturing: a) cognitive symptoms not easily detected using neuropsychological tests; b) neurobehavioral symptoms that can be confused with psychological symptoms, and c) causal beliefs that may affect how people cope with these symptoms. Effective interventions are needed to assist prostate cancerpatients in managing these symptoms.
Authors: Kristine A Donovan; Lauren M Walker; Richard J Wassersug; Lora M A Thompson; John W Robinson Journal: Cancer Date: 2015-09-15 Impact factor: 6.860
Authors: Lisa M Wu; Ali Amidi; Molly L Tanenbaum; Gary Winkel; Wayne A Gordon; Simon J Hall; Katrin Bovbjerg; Michael A Diefenbach Journal: Support Care Cancer Date: 2017-12-27 Impact factor: 3.603
Authors: Andrea Kokorovic; Alan I So; Hosam Serag; Christopher French; Robert J Hamilton; Jason P Izard; Jasmir G Nayak; Frédéric Pouliot; Fred Saad; Bobby Shayegan; Armen Aprikian; Ricardo A Rendon Journal: Can Urol Assoc J Date: 2022-08 Impact factor: 2.052
Authors: Sabine Deprez; Shelli R Kesler; Andrew J Saykin; Daniel H S Silverman; Michiel B de Ruiter; Brenna C McDonald Journal: J Natl Cancer Inst Date: 2018-03-01 Impact factor: 13.506
Authors: Daniel J Tobiansky; Kathryn G Wallin-Miller; Stan B Floresco; Ruth I Wood; Kiran K Soma Journal: Front Endocrinol (Lausanne) Date: 2018-06-05 Impact factor: 5.555
Authors: Jaime L Palmer-Hague; Vivian Tsang; Charlenn Skead; Richard J Wassersug; Eleni Nasiopoulos; Alan Kingstone Journal: Sex Med Date: 2017-12 Impact factor: 2.491